Comparative Pharmacology
Head-to-head clinical analysis: CLARITHROMYCIN versus ERYMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITHROMYCIN versus ERYMAX.
CLARITHROMYCIN vs ERYMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically to the 23S rRNA component, blocking peptide chain elongation and exerting bacteriostatic or bactericidal effects depending on concentration and organism.
Erythromycin acts by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis. It also acts as a motilin receptor agonist, stimulating gastrointestinal motility.
250-500 mg orally twice daily for 7-14 days; for MAC infection: 500 mg twice daily.
250-500 mg orally every 6 hours or 500-1000 mg intravenously every 6 hours.
None Documented
None Documented
Terminal elimination half-life: 5-7 hours in adults with normal renal function; prolonged to 8-12 hours in moderate to severe renal impairment; clinical context: allows twice-daily dosing; active metabolite (14-hydroxyclarithromycin) half-life similar.
Clinical Note
moderateClarithromycin + Levofloxacin
"Clarithromycin may increase the QTc-prolonging activities of Levofloxacin."
Clinical Note
moderateClarithromycin + Norfloxacin
"Clarithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateClarithromycin + Gemifloxacin
"Clarithromycin may increase the QTc-prolonging activities of Gemifloxacin."
Clinical Note
moderateClarithromycin + Haloperidol
Terminal elimination half-life: 1.5–2 hours in adults; prolonged to 4–6 hours in hepatic impairment; requires dosing adjustment in cirrhosis.
Renal: approximately 30-40% unchanged; biliary/fecal: approximately 40-50% as metabolites; total renal clearance accounts for about 30-40% of dose; hepatic metabolism contributes to elimination; dose adjustment required in severe renal impairment (CrCl <30 mL/min).
Renal excretion of unchanged drug: 10–15%; biliary/fecal excretion: 85–90% as active metabolites.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic
"Clarithromycin may increase the QTc-prolonging activities of Haloperidol."